Literature DB >> 8625279

Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation.

R A Faust1, M Gapany, P Tristani, A Davis, G L Adams, K Ahmed.   

Abstract

We hypothesized that malignant transformation of normal mucosa of the upper aerodigestive tract to squamous cell carcinoma of the head and neck (SCCHN) might be associated with altered CK2 activity in the chromatin compartment of these tumors. We measured CK2 activity in the cytosol and chromatin of 7 surgical specimens of SCCHN, and 5 specimens of normal oropharyngeal mucosa from non-smokers/non-drinkers. CK2 activity in SCCHN tumors was significantly elevated in both the nuclear chromatin (P < 0.0005) and cytosolic (P <0.04) compartments relative to normal mucosa. These data suggest that activation of dysregulation of the chromatin-associated CK2 signal may play a role in the pathobiology od SCCHN.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8625279     DOI： 10.1016/0304-3835(96)04110-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  61 in total

1.  Multiple forms of protein kinase CK2 present in leukemic cells: in vitro study of its origin by proteolysis.

Authors:  J Roig; A Krehan; D Colomer; W Pyerin; E Itarte; M Plana
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

2.  Environmental reprogramming of the expression of protein kinase CK2beta subunit in fish.

Authors:  M Alvarez; G Kausel; J Figueroa; M I Vera
Journal:  Mol Cell Biochem       Date:  2001-11       Impact factor: 3.396

3.  Transcriptional coordination of the genes encoding catalytic (CK2alpha) and regulatory (CK2beta) subunits of human protein kinase CK2.

Authors:  W Pyerin; K Ackermann
Journal:  Mol Cell Biochem       Date:  2001-11       Impact factor: 3.396

4.  Assembly of protein kinase CK2: investigation of complex formation between catalytic and regulatory subunits using a zinc-finger-deficient mutant of CK2beta.

Authors:  D A Canton; C Zhang; D W Litchfield
Journal:  Biochem J       Date:  2001-08-15       Impact factor: 3.857

Review 5.  Emergence of protein kinase CK2 as a key target in cancer therapy.

Authors:  Janeen H Trembley; Zhong Chen; Gretchen Unger; Joel Slaton; Betsy T Kren; Carter Van Waes; Khalil Ahmed
Journal:  Biofactors       Date:  2010 May-Jun       Impact factor: 6.113

Review 6.  Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.

Authors:  David W Litchfield
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

7.  CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.

Authors:  Matthew S Brown; Oumou T Diallo; Michael Hu; Reza Ehsanian; Xinping Yang; Pattatheyil Arun; Hai Lu; Vicci Korman; Gretchen Unger; Khalil Ahmed; Carter Van Waes; Zhong Chen
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

8.  Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues.

Authors:  Fatima Qaiser; Janeen H Trembley; Sarah Sadiq; Iqbal Muhammad; Rubina Younis; Shoaib Naiyar Hashmi; Badar Murtaza; Thomas S Rector; Abdul Khaliq Naveed; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2016-07-19       Impact factor: 3.396

9.  Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines.

Authors:  Keya Bandyopadhyay; Ruth A Gjerset
Journal:  Biochemistry       Date:  2011-01-12       Impact factor: 3.162

10.  Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation.

Authors:  Kevin N Dietz; Patrick J Miller; Andrew D Hollenbach
Journal:  Biochemistry       Date:  2009-12-15       Impact factor: 3.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.